Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
(+)-α-dihydrotetrabenazine in moderate to severe tardive dyskinesia – open-label safety study
2023-509518-12-01Phase 2Authorised
- Sponsor
- Adeptio Pharmaceuticals
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of (+)-α-dihydrotetrabenazine in tardive dyskinesia (TD), sponsored by Adeptio Pharmaceuticals. Primary endpoint: Change in AIMS score (items 1-7). Planned start Apr 2024; status: authorised.
02
Drugs
(+)-α-dihydrotetrabenazine
03
Conditions
tardive dyskinesia (TD)
Beyond the preview
Go deeper on 2023-509518-12-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509518-12-01.